Investigational drug · Phase 3
VRDN-003
Also called: ZL-1109
Not approved by FDA. In 5 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Thyroid Eye Disease, Thyroid Eye Disease (TED).
Phase 3Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
5
4 still active
All registered trials
5
Any phase or sponsor naming "VRDN-003"
First trial start
2024
Aug 27, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "VRDN-003", any sponsor or status.
Conditions studied
As listed on its trial records.
- Thyroid Eye Disease
- Thyroid Eye Disease (TED)
Approved drugs for the same conditions: Endocrinology and women's health
Largest trials
Live from ClinicalTrials.gov: studies naming "VRDN-003" as an intervention, largest first.
- A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)Pivotal-lookingActive, not recruiting
Viridian Therapeutics, Inc.Industry
NCT06812325 · 320 participants · Start Feb 3, 2025 · Primary completion Apr 22, 2026
Drug: VRDN-003; Placebo · For: Thyroid Eye Disease (TED)
Sites: Tuscon, Arizona; Inglewood, California; Newport Beach, California · 64 sites in all
- An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)Pivotal-lookingActive, not recruiting
Viridian Therapeutics, Inc.Industry
NCT06625398 · 204 participants · Start Aug 27, 2024 · Primary completion Mar 4, 2026
Drug: VRDN-003; Placebo · For: Thyroid Eye Disease
Sites: Scottsdale, Arizona; Canoga Park, California; Huntington Beach, California · 60 sites in all
- An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)Pivotal-lookingActive, not recruiting
Viridian Therapeutics, Inc.Industry
NCT06625411 · 132 participants · Start Aug 27, 2024 · Primary completion Feb 12, 2026
Drug: VRDN-003; Placebo · For: Thyroid Eye Disease
Sites: Scottsdale, Arizona; Canoga Park, California; Huntington Beach, California · 48 sites in all
- A Study to Assess the Efficacy and Safety of ZL-1109 in Chinese Participants With Active Thyroid Eye DiseasePivotal-lookingActive, not recruiting
Zai Lab (Shanghai) Co., Ltd.Industry
NCT07211776 · 108 participants · Start Dec 5, 2025 · Primary completion Mar 14, 2027
Drug: ZL-1109 (VRDN-003); Placebo · For: Thyroid Eye Disease (TED)
Sites: Beijing, China; Bengbu, China; Changsha, China · 26 sites in all
- A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)Pivotal-lookingCompleted
Viridian Therapeutics, Inc.Industry
NCT07155668 · 87 participants · Start Jul 1, 2025 · Primary completion May 28, 2026
Drug: VRDN-003 · For: Thyroid Eye Disease
Sites: Inglewood, California; Cape Coral, Florida; Kissimmee, Florida · 13 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Emerging therapies in the medical management of thyroid eye disease.
Kamboj A, Harrison AR, Mokhtarzadeh A · Front Ophthalmol (Lausanne) 2023
Also in development for Thyroid Eye Disease
- BatoclimabIMVT-1401Phase 33 trials
Immunovant Sciences GmbH · Thyroid Eye Disease, Graves Disease
- IBI311Phase 33 trials
Innovent Biologics (Suzhou) Co. Ltd. · Thyroid Eye Disease, Thyroid Eye Disease, TED
- PacibekitugTOUR006, PAC001Phase 33 trials
Tourmaline Bio, Inc., a Novartis Company · Myocardial Infarction, Thyroid Eye Disease, Chronic Kidney Diseases
- KHN939Phase 32 trials
Beijing Kanghong Biological Medicine Co., Ltd. · Thyroid Eye Disease
- linsitinibPhase 32 trials
Sling Therapeutics, Inc. · Graves Orbitopathy, Thyroid Eye Disease, TED, Thyroid Eye Disease
- AMG 732Phase 22 trials
Amgen · Thyroid Eye Disease
- LASN01Phase 22 trials
Lassen Therapeutics 1 PTY LTD · Thyroid Eye Disease, Pulmonary Fibrosis, Graves Ophthalmopathy
- lonigutamabPhase 21 trial
ACELYRIN Inc. · Thyroid Eye Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.